Skip to main content

Advertisement

Table 2 Most common AEs by treatment cycle in patients with best response of SD to romidepsin

From: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Drug related/non-drug related, n Treatment cycle
Any (n = 32) 1 (n = 32) 2 (n = 28) 3 (n = 25) 4 (n = 21) 5 (n = 14) 6 (n = 11) >6 (n = 5)
Any grade AEs reported in > 20 % of patients with best response of SD
 Nausea 22/2 18/2 6/0 5/0 5/1 5/0 0/0 1/0
 Asthenia/fatigue 19/1 13/0 6/0 4/0 4/0 3/1 2/1 1/0
 Infections SOC 6/11 4/6 1/3 1/2 0/5 1/1 1/2 1/2
 Dysgeusia 14/0 8/0 7/0 1/0 2/0 0/0 0/0 0/0
 Vomiting 12/1 5/0 4/1 4/0 3/1 4/0 0/0 1/0
 Diarrhea 7/5 5/1 4/2 1/0 1/0 0/1 0/1 1/0
 Constipation 5/6 3/3 0/0 2/0 0/0 1/1 0/0 0/1
 Anorexia 11/0 6/0 3/0 3/0 1/0 2/0 0/0 1/0
 Thrombocytopenia 10/0 6/0 2/0 3/0 2/0 2/0 2/0 0/0
 Pyrexia 7/1 1/1 1/0 0/1 2/1 1/1 1/1 1/1
 Neutropenia 7/0 4/0 4/0 3/0 2/0 1/0 1/0 2/0
 Anemia 6/1 1/1 2/0 1/0 1/0 0/0 1/0 2/0
Grade ≥ 3 AEs reported in > 1 patients with best response of SD
 Neutropenia 7/0 4/0 3/0 2/0 1/0 1/0 0/0 2/0
 Thrombocytopenia 6/0 3/0 1/0 1/0 1/0 1/0 1/0 0/0
 Infections SOC 2/3 1/2 0/0 0/0 0/0 0/0 1/0 0/2
 Anemia 3/0 0/0 1/0 0/0 0/0 0/0 1/0 1/0
  1. Patients who experienced drug-related events may have also experienced non-drug-related events
  2. SOC system organ class